1 | 14C]-RPC1063 Solution (0.1 mg/mL) for Oral Administration | - | - | - | - | [3] 13 13, 96, 97 |
2 | ADMINISTRATION | - | - | - | - | [1] 19 19 |
3 | Administration of a high dose of desipramine | [1] Desipramine Desipramine | [1] D07791
D07791
| [2] SLC6A2 SLC6A2, SLC6A4 💬 | [2] Serotonergic synapse Serotonergic synapse, Synaptic vesicle cycle 💬 | [1] 156 156 |
4 | Administration of a low dose of desipramine | [1] Desipramine Desipramine | [1] D07791
D07791
| [2] SLC6A2 SLC6A2, SLC6A4 💬 | [2] Serotonergic synapse Serotonergic synapse, Synaptic vesicle cycle 💬 | [1] 156 156 |
5 | Administration of an ACE-inhibitor or not | - | - | - | - | [1] 210 210 |
6 | Administration of Cimzia® | [1] Certolizumab pegol Certolizumab pegol | [1] D03441
D03441
| [1] TNF TNF 💬 | [67] AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | [1] 46 46 |
7 | Administration of drug (Interferon-gamma 1-b) subcutaneously | - | - | - | - | [1] 65 65 |
8 | Administration of Methylprednisolone + Prednisone + Mycophenolate mofetil | [4] Methylprednisolone Methylprednisolone, Mycophenolate mofetil, Mycophenolic acid, Prednisone | [4] D00407
D00407
,
D00473
,
D00752
,
D05096
| [3] IMPDH1 IMPDH1, IMPDH2, NR3C1 💬 | [5] Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Neuroactive ligand-receptor interaction, Nucleotide metabolism, Purine metabolism 💬 | [1] 49 49 |
9 | Administration of methylprednisolone, paracetamol and dexchlorpheniramine | [3] Acetaminophen Acetaminophen, Dexchlorpheniramine, Methylprednisolone | [3] D00217
D00217
,
D00407
,
D07803
| [4] HRH1 HRH1, NR3C1, PTGS1, PTGS2 💬 | [26] Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Calcium signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Inflammatory mediator regulation of TRP channels, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Neuroactive ligand-receptor interaction, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | [1] 49 49 |
10 | Administration of rituximab and methylprednisolone | [2] Methylprednisolone Methylprednisolone, Rituximab | [2] D00407
D00407
,
D02994
| [2] MS4A1 MS4A1, NR3C1 💬 | [2] Hematopoietic cell lineage Hematopoietic cell lineage, Neuroactive ligand-receptor interaction 💬 | [1] 51 51 |
11 | Administration of stable isotope-labelled leucine- | [1] Leucine Leucine | [1] D00030
D00030
| - | - | [1] 6 6 |
12 | Avandia administration for 6-12 weeks | - | - | - | - | [1] 265 265 |
13 | Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL) | [1] Human immunoglobulin G Human immunoglobulin G | - | - | - | [1] 14 14 |
14 | Bosentan administration | [1] Bosentan Bosentan | [2] D01227
D01227
,
D07538
| [2] EDNRA EDNRA, EDNRB 💬 | [9] Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | [1] 86 86 |
15 | CS1 Administration | - | - | - | - | [1] 86 86 |
16 | Docosahexaenoic acid administration: 50 mg/kg/day during 12 months | [1] Doconexent Doconexent | - | - | - | [1] 299 299 |
17 | Experimental: CRH administration | - | - | - | - | [2] 72 72, 78 |
18 | Experimental: GLP1-RA (exenatide) administration | [1] Exenatide Exenatide | [1] D04121
D04121
| [1] GLP1R GLP1R 💬 | [3] Insulin secretion Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | [2] 72 72, 78 |
19 | Growth hormone administration for 6 months | [1] Somatotropin Somatotropin | - | - | - | [1] 78 78 |
20 | Human normal 10% immunoglobulin for intravenous administration | [1] Human immunoglobulin G Human immunoglobulin G | - | - | - | [1] 14 14 |
21 | Human normal 10% immunoglobulin for intravenous administrationn | [1] Human immunoglobulin G Human immunoglobulin G | - | - | - | [1] 14 14 |
22 | Human normal immunoglobulin for intravenous (IV) administration | [1] Human immunoglobulin G Human immunoglobulin G | - | - | - | [1] 51 51 |
23 | Human normal immunoglobulin for intravenous administration | [1] Human immunoglobulin G Human immunoglobulin G | - | - | - | [3] 14 14, 51, 65 |
24 | Human normal immunoglobulin for subcutaneous administration | [1] Human immunoglobulin G Human immunoglobulin G | - | - | - | [2] 51 51, 65 |
25 | Human Normal Immunoglobulin for Subcutaneous Administration (IGSC) | [1] Human immunoglobulin G Human immunoglobulin G | - | - | - | [1] 65 65 |
26 | Intracerebral administration of AAVrh.10cuARSA | - | - | - | - | [1] 19 19 |
27 | Intrathecal administration of autologous MSC-NP | - | - | - | - | [1] 13 13 |
28 | Intravenous administration of 1 million of MSC | - | - | - | - | [1] 2 2 |
29 | Intravenous administration of 2 million of MSC | - | - | - | - | [1] 2 2 |
30 | Intravenous administration of 4 million of MSC | - | - | - | - | [1] 2 2 |
31 | Intravenous administration of ferric carboxymaltose | [1] Ferric carboxymaltose Ferric carboxymaltose | [1] D08920
D08920
| - | - | [1] 86 86 |
32 | Kiovig® (Human normal Immunoglobulin for intravenous administration 100mg/mL) | [1] Human immunoglobulin G Human immunoglobulin G | - | - | - | [1] 14 14 |
33 | Levodopa (drug), intraduodenal administration | [1] Levodopa Levodopa | [1] D00059
D00059
| [5] DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | [11] Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | [1] 6 6 |
34 | Levodopa and carbidopa solution for SC administration | [2] Carbidopa Carbidopa, Levodopa | [2] D00059
D00059
,
D00558
| [6] DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | [16] Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | [1] 6 6 |
35 | Methotrexate(MTX) administration is at the discretion of the rheumatologist and no tradename is fixed by the protocol | [1] Methotrexate Methotrexate | [1] D00142
D00142
| [2] DHFR DHFR, DHFR2 💬 | [5] Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | [1] 46 46 |
36 | Methotrexate(MTX) administration is at the discretion of the rheumatologist and no tradename is fixed by the protocol. | [1] Methotrexate Methotrexate | [1] D00142
D00142
| [2] DHFR DHFR, DHFR2 💬 | [5] Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | [1] 46 46 |
37 | Obinutuzumab administration | [1] Obinutuzumab Obinutuzumab | [1] D09321
D09321
| [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 49 49 |
38 | QR-313 Gel for Topical (Cutaneous) Administration | - | - | - | - | [1] 36 36 |
39 | RAAV1-CMV-GAA (study agent) Administration | - | - | - | - | [1] 256 256 |
40 | Routine steroid administration group | - | - | - | - | [1] 85 85 |
41 | Semi continuous intra-oral administration of LD/CD | - | - | - | - | [1] 6 6 |
42 | Subcutanious administration | - | - | - | - | [1] 46 46 |
43 | Subretinal administration of rAAV2-VMD2-hMERTKRecombinant Adeno-Associated Virus | - | - | - | - | [1] 90 90 |